FilingReader Intelligence
Nxera Pharma reports Q1 results, outlines strategic progress for 2025
May 2, 2025 at 12:05 PM UTC•By FilingReader AI
Nxera Pharma (TSE: 4565) today announced its Q1 2025 consolidated financial results, alongside key operational highlights and strategic developments. Revenue reached JPY6,644 million, up JPY2,033 million from Q1 2024, fueled by sales of QUVIVIQ® and R&D milestone achievements. The company reported a net loss of JPY760 million, an improvement from the JPY3,281 million loss in the same period last year.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025May 2, 2025 at 06:36 AM UTC
Summary of first quarter financial results for the fiscal year ending December 2025 [IFRS] (consolidated)May 2, 2025 at 06:36 AM UTC
Business highlights and consolidated financial results for the first quarter (January-March) of the fiscal year ending December 2025May 2, 2025 at 06:36 AM UTC
TSE:4565•Tokyo Stock Exchange
News Alerts
Get instant email alerts when Sosei Group Corporation publishes news
Free account required • Unsubscribe anytime